

Tirzepatide (Mounjaro) implementation update 23 June 25

Thank you for your continued patience whilst we have been working on the NHS England implementation requirements in preparation for 23 June 2025. There are a couple of items that are in progress still for implementation to commence. Here is an update:

Primary Care Delivery Model and offer to Practices – Practices will receive an Expressions of Interest (EOI) and a LES service specification for the delivery of Tirzepatide in primary care for weight management from the primary care contracts team imminently. We would be very grateful if Practices could make returns as soon as possible so we can mitigate any potential gaps in delivery.

NHSE Digital Wraparound Care (WAC) provider – the WAC mandated by NICE alongside Tirzepatide prescribing that provides patients with nutrition and dietetic advice, physical activity and functional movement, behavioural support and lifestyle change tools alongside Tirzepatide prescribing will be delivered by NHSE Diabetes Prevention Programme (NDPP); in BNSSG this is Living Well Taking Control.

A reminder that patients will be provided with Behavioural Support for Obesity Prescribing (BSOP) accessed from primary care as a 9-month programme. Patients will be offered a choice of three delivery models:

1. Face to face group sessions – traditional format with peer interaction within community settings.
2. Remote digital groups sessions – live, interactive support via video conferencing.
3. Fully digital delivery – Flexible 1-1 support via the Liva Healthcare App using a smart phone or tablet.

The referral form has now been received and will be available on the referral website on Remedy. Referral for BSOP is **only for patients who meet the NHSE year 1 cohort 1 criteria** and decide to take up the offer of Tirzepatide treatment.

NHSE year 1 cohort 1

A reminder that the primary care eligibility criteria for the NHSE cohort 1 in Year 1 is as follows:

- BMI ≥ 40 and
- ≥ 4 'qualifying' comorbidities – hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus

Use a lower BMI threshold (usually reduced by 2.5 kg/m²) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

Searches to support Practices to find their potentially eligible populations have been compiled by the Medicines Optimisation team and shared with Practices.

Please contact bnssg.medicines-optimisation@nhs.net if you would like them to be sent again.

Support Practices with patient flow – we have developed some wording for text messaging that Practices may wish to adopt/adapt to send to patients that may be eligible for Tirzepatide treatment. We have considered the words used to provide a compassionate and supportive approach.

We have reviewed the records we have for you and note that you may be eligible for treatment with Tirzepatide (Mounjaro) for weight management to help improve health and wellbeing with support. If you are happy to speak with us about this, please get in contact to make an appointment and find out more.

Training for Primary Care – a live Teams webinar for Practices was held on Wednesday 11 June 25 and was recorded. Practice staff who registered for the event and attended the session should have received a link to the recorded webinar and a copy of the slide deck.

If you would like a link to the recorded webinar and copy of the slide deck please contact bnssg.medicines-optimisation@nhs.net.

GP IT template – NHSE have generated new SNOMED codes to capture Tirzepatide implementation and are developing a national template. There is a delay from NHSE and we have not received this template yet. We are hoping that this will be a helpful clinical tool but preparing to develop a local one if it is not. We will keep you updated.

Patient Information and communication – NHSE have provided FAQs for patients and this can be found on the Joint Formulary Remedy website - [Tirzepatide FAQs for patients](#)

Further information can be found on Remedy at [Weight Management - Tirzepatide \(Mounjaro\) \(Remedy BNSSG ICB\)](#)

We will update you with further information as soon as it becomes available to share with you. bnssg.medicines-optimisation@nhs.net